RARuth Em Ashton

Ruth Em Ashton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruth Em Ashton has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blood biomarkers of long COVID: A cross-sectional evaluation of key cytokines and the coordination of inflammation

    by Callum Thomas, Ruth E. Ashton, Etheresia Pretorius, Rebecca Owen, Massimo Nunes, Jan H. Pretorius, Isaac T. Shawa, Corinna Chidley, Mark A. Faghy

    Introduction: Long COVID is a complex pathophysiological condition linked to a heterogenous symptom profile. Dysregulation of 1) immunological and inflammatory responses, 2) endothelial/vascular function, and 3) metabolic and clotting processes have been identified; however, there remains a lack of clinically validated diagnostic biomarkers. The study aim was to investigate dysregulation of cytokines, chemokines and growth factors in confirmed Long COVID cases grouped by disease severity. Methods: One-hundred-and-twenty-seven participants provided venous blood samples for cytokine profiling utilising Luminex assays. Participants were grouped into those with no knowledge of SARS-CoV-2 infection (n = 21), acute infection within 3-months (n = 22), spontaneous resolvers (>3-months, n = 21) and those with confirmed Long COVID (n = 63). Long COVID severity was grouped according to the post-COVID-19 functional status (PCFS) and defined as those with negligible (4A; n = 9), mild (4B; n = 20), moderate (4C; n = 24), and severe limitations (4D; n = 10). Cytokines were assessed for normality using Shapiro-Wilk tests and differences measured between groups using Kruskal-Wallis tests. Pairwise correlation and principal component analysis were performed. Results: Interleukin-12 (p40/p70) was 22% greater in the Long COVID group (Median [IQR]: 58 [49] pg/mL, p = 0.046) and 30% greater in the acutely infected group (64 [36] pg/mL; p = 0.039) against non-infected controls (45 [25] pg/mL). Following PCFS classification, fibroblast growth factor-basic was 25% lower in Long COVID 4B versus spontaneous resolvers (24 [7] vs. 32 [24] pg/mL; p = 0.025). Pairwise correlation differences demonstrated that three Long COVID subgroups had strong, positive associations between cytokines when compared to non-infected controls; however, PCA was unable to determine any coordinated cytokine variation that was group specific. Discussion and conclusions: Elevated interleukin-12 (p40/p70) and reduced basic fibroblast growth factor suggest persistent immune activation and possible subgroup-specific Long COVID; however, these findings were marginally significant and exploratory. A coordinated but partial immunological/inflammatory profile may exist in some of those with Long COVID, suggesting a rationale for subgrouping upon a biological, rather than self-report basis but larger longitudinal studies are required to confirm this hypothesis.

  • Open Access

    An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial

    by Mark A Faghy, Jade Chynoweth, Anton Barnett, Lindsay Skipper, Victoria Allgar, Helen Neilens, Kayle-Anne Sands, Amber Lord, Helen Hambly, Paigan J Aspinall, et al.

    Objective: Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the feasibility of a five‑day IV remdesivir intervention for individuals with LC. Methods: Seventy-three participants aged ≥18 years with a confirmed LC diagnosis were recruited across two sites in the United Kingdom to receive a five‑day course of IV remdesivir. Primary feasibility outcomes included recruitment, treatment completion, acceptability, and safety. Exploratory patient-reported (e.g. Fatigue Assessment Scale [FAS]) and clinical outcomes (e.g. 6-minute walk test [6MWT]) were also collected. Results: Of 106 individuals screened, 73 were enrolled and 71 (97%) completed the 5-day IV remdesivir regimen. Follow-up assessments were completed by 70 participants (96%), with high completion rates observed across clinical assessments, patient-reported outcomes and symptom tracking. No severe adverse reactions were reported. Improvements were also observed in several exploratory patient-reported and clinical outcomes. Conclusion: We demonstrated the feasibility and acceptability of administering IV remdesivir in people with LC. Analysis of secondary outcomes suggests therapeutic promise, but rigorous evaluation in large-scale randomised controlled trials is essential to determine the true efficacy and clinical utility of intravenous remdesivir in this population.

  • Open Access

    An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID

    by Helen Neilens, Victoria Allgar, Kayle-Anne Sands, Jade Chynoweth, Amber Lord, Paigan J. Aspinall, Helen Hambly, Anton Barnett, Lindsay Skipper, Tom Bewick, et al.

    Background: Long COVID (LC) affects around two million people in the United Kingdom and over 65 million people globally. Antiviral medications have shown positive effects in reducing the risk of progression to severe disease in high-risk patients during an acute SARS-CoV-2 infection and improved outcomes in those living with LC. Research testing the feasibility and efficacy of anti-viral medications is ongoing, and clinical trials should determine the use of Remdesivir and its impact on LC symptoms, patient-reported outcomes, quality of life and functional status. Methods: Seventy-two patients ≥ 18 years of age who have a confirmed LC diagnosis will be recruited across two sites to trial Remdesivir TM treatment delivered via intravenous infusion over 5 days. This feasibility study will provide high-quality data to estimate screening rates, recruitment through different pathways, retention and treatment adherence. The study will also determine the definitive trial’s most clinically relevant primary outcome. After a detailed screening process, patient-reported and clinical outcome measures (including EQ-5D-5L, Symptom Burden Questionnaire™ for LC [SBQ™], cardio-pulmonary exercise tests (CPET), lung function, biomarkers and inflammatory profiles) will be collected to determine symptoms and impact of their condition, which will be repeated post-treatment. A subset of 20 participants will undergo parametric [ 18 ] Fluorodeoxyglucose (FDG) to measure multi-organ metabolic activity. Due to the established physical, cognitive and clinical impairment impacts of LC, patient involvement has been extensively embedded within the design and implementation of all study processes to increase patient safety and delivery. Discussion: This study will provide data on the feasibility of a trial of 5-day intravenous treatment with Remdesivir for patients with LC. The treatment is already effective in the treatment of patients with acute severe cases of SARS-CoV-2. Remdesivir has an established safety profile and carries no higher risk to patients than standard medical care. The findings will inform the design of a future definitive study. Registration details ISRCTN Number: 72940450 Date registered: 07/06/2024 URL: https://www.isrctn.com/ISRCTN72940450 ClinicalTrials.gov Number: NCT05911906

  • Open Access

    Profiling the persistent and episodic nature of long COVID symptoms and the impact on quality of life and functional status: a cohort observation study

    by Rebecca Owen, Ruth Em Ashton, Tom Bewick, Robert J Copeland, Francesco V Ferraro, Clare Kennerley, Bethan E Phillips, Thomas Maden-Wilkinson, Thomas Parkington, Lindsay Skipper, et al.

    Symptoms of acute viral infections that persist in the weeks, months, and years’ post-infection are collectively referred to as post-viral illnesses. The most devastating epidemic in recorded history was the 1918 Spanish Flu epidemic, with an estimated global mortality between 24–50 million people over three distinct waves of infection [1]. Of particular interest was the […]


  • Open Access

    Forming a consensus opinion to inform long COVID support mechanisms and interventions: a modified Delphi approach

    by Rebecca Owen, Ruth E.M. Ashton, Francesco V. Ferraro, Lindsay Skipper, Tom Bewick, Paul Leighton, Bethan E. Phillips, Mark A. Faghy


  • Top Cited Papers
    Open Access

    Lived experience of patients with Long COVID: a qualitative study in the UK

    by Callum Thomas, Mark A Faghy, Rebecca Owen, James Yates, Francesco Ferraro, Tom Bewick, Kate Haggan, Ruth E M Ashton

    Background Long COVID is a rapidly evolving global health crisis requiring interdisciplinary support strategies that incorporate the lived experience of patients. Currently, there is a paucity of research documenting the day-to-day experiences of patients living with Long COVID. Objective To explore the lived experience of Long COVID patients. Study design Longitudinal, observation study. Setting An inductive, data-driven, qualitative approach was used to evaluate hand-written diaries obtained from individuals who had been referred to a Derbyshire Long COVID clinic. Participants 12 participants (11 females, age 49±10 years, 11 Caucasians) were recruited. Participants were included if they had a previous confirmed or suspected COVID-19 infection with ongoing recovery, >18 years old, understood the study requirements and provided informed consent. Method Participants were directed to complete self-report diaries over 16 weeks. Responses were transcribed verbatim and analysed using thematic analysis. Results Three key themes were highlighted: (1) understanding who helps patients manage symptoms, (2) daily activities and the impact on quality of life and health status and (3) the effect of turbulent and episodic symptom profiles on personal identity and recovery. Conclusions The novel challenges presented by Long COVID are complex with varying inter-related factors that are broadly impacting functional status and quality of life. Support mechanisms must incorporate the lived experiences and foster true collaborations between health professionals, patients and researchers to improve patient outcomes. Trial registration number NCT04649957.


  • Open Access

    Is long COVID the next global health crisis?

    by Mark A Faghy, Rebecca Owen, Callum Thomas, James Yates, Francesco V Ferraro, Lindsay Skipper, Sarah Barley-McMullen, Darren A Brown, Ross Arena, Ruth Em Ashton

    The rapid development and deployment of coronavirus disease 2019 (COVID-19) vaccines should be heralded as a feat of true scientific collaboration that saved millions of lives [1]. Despite the success, vaccines do not offer complete protection against infection, mild, and severe disease [2–5] and the development of a long-term complex symptom profile, commonly referred to […]


  • Open Access

    Post-acute COVID syndrome (long COVID): What should radiographers know and the potential impact for imaging services

    by F. Alghamdi, R. Owen, R.E.M. Ashton, A.D. Obotiba, R.M. Meertens, E. Hyde, M.A. Faghy, K.M. Knapp, P. Rogers, W.D. Strain


  • Integrated sports and respiratory medicine in the aftermath of COVID-19

    by Mark A Faghy, Ruth Em Ashton, Tom M Maden-Wilkinson, Robert J Copeland, Thomas Bewick, Andy Smith, Mike Loosemore


  • Open Access

    Cross-sectional study of patient-reported fatigue, physical activity and cardiovascular status in men after robotic-assisted radical prostatectomy

    by Ruth E. Ashton, Garry A. Tew, Wendy A. Robson, John M. Saxton, Jonathan J. Aning

    Patient-reported fatigue after robotic-assisted radical prostatectomy (RARP) has not been characterised to date. Fatigue after other prostate cancer (PCa) treatments is known to impact on patient-reported quality of life. The aim of this study was to characterise fatigue, physical activity levels and cardiovascular status post-RARP.